Navigation Links
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Date:6/30/2008

gulatory filings for marketing approval is underway. Discussions for license and distribution agreements in other major markets are in progress. Anesiva also has established a joint venture in China for the assembly of Zingo devices using U.S.-sourced components.

About Zingo

Peripheral venous access procedures are among the most frequently reported painful events in hospitalized children.(1) The American Pain Society and the American Academy of Pediatrics, among other organizations, have developed recommendations that emphasize the importance of minimizing procedural pain in children whenever possible.(2) However, despite the existence of these recommendations, children undergoing these procedures remain largely under- treated.(3)

Zingo is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local analgesia to reduce the pain associated with peripheral IV insertions or blood draws, approved for use in children aged three to 18. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. In clinical trials, the most common adverse events with Zingo were redness, red dots and swelling. For full Zingo prescribing information, go to http://www.zingo.com.

A supplemental New Drug Application (sNDA) is under FDA review to expand Zingo's indicated use to include adults. FDA action on the sNDA is anticipated by January 2009, based on the standard review period under the Prescription Drug User Fee Act (PDUFA).

Conference Call and Webcast

Anesiva management will host a conference call and webcast at 10:00 am Pacific time (1:00 pm Eastern time) today to discuss the Zingo commercial launch. Interested parties can listen to the live audio webcast by dialing (866) 616-3642 (international dial: (706) 643-3817) or by logging on to '/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
2. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
3. Anesiva Announces First Quarter 2008 Financial Results
4. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
5. Anesiva Announces Expansion of Zingo Agreement in Europe
6. Anesiva Announces New Zingo Marketing and Distribution Agreement
7. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
8. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
9. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... - 2014 Summary Global Markets Direct,s, ... - 2014, provides an overview of the Pacific ... This report provides comprehensive information on the ... LLC,s, complete with comparative analysis at various stages, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... September 30, 2014 Shimadzu Scientific ... an easy-to-use and highly precise tool for measuring ... considerable elongation. With 1000-mm maximum movement distance, the ... for a gauge length of 10 mm. In ... accuracy above 50-mm stroke and within +/- 100 ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... ... as the sample collection kit for MyCeliacID™ a saliva-based genetic test dedicated to celiac ... sample collection challenges inherent with traditional collection methods which are often too costly and ... Ottawa, ...
... , CANTON, Mass., Aug. 18 ... than 500 pieces of state-of-the-art R&D equipment that is no ... EquipNet as the exclusive seller and listed the premium lab ... online venue for pre-owned equipment. , , ...
... , , , , ... Inc., (NYSE: CRY ) an implantable biological medical device ... of the CryoPatch((R)) SG pulmonary human cardiac patch since FDA clearance. ... of Michigan C.S. Mott Children,s Hospital in Ann Arbor, MI by ...
Cached Biology Technology:DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Massive Inventory of Premium Lab & Analytical Equipment Now Available 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 3CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 4
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... FL. If you think you eat healthier at the Sunburst ... be wrong. You could be a victim of the "Health ... Consumer Research conference in Jacksonville, FL, showed that people eating ... 56% as many calories as they actually did. The ...
... direct evidence that taking up smoking results in epigenetic changes ... reported at the 35th Congress of the European Society for ... smoking and cancer has been established for decades, explained Dr ... Cancer Studies, Birmingham, who presented the results. Smoking is the ...
... lung cancer patients seem to live longer and experience delays ... cancer-associated molecule called MET is added to treatment with erlotinib, ... Dr David Spigel, Director of lung cancer research for the ... findings at the 35th Congress of the European Society for ...
Cached Biology News:Study reveals cancer-linked epigenetic effects of smoking 2New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2